Drug Use Analysis on Over-60-year Inpatients with Lung Cancer in the West China Hospital of Sichuan University in 2011_Chinese Journal of Evidence-Based Medicine

Authors：

 LUJing ¹ ,  XUTing ¹ ,  LIYou-ping ² , WUBin ¹ , YINXi ¹ , ZHANMei ¹ , XIAOGui-rong ¹ , ZHANGYing ¹

1. Department of Pharmacy, West China Hospital, Sichuan University, Chengdu 610041, China;
2. Chinese Evidence-Based Medicine Center, West China Hospital, Sichuan University, Chengdu 610041, China;

Corresponding?author：

XUTing, Email: tingx2009@163.com; LIYou-ping, Email: yzmylab@hotmail.com

Keywords：

Lung cancer; Elderly; Inpatient; Drug use analysis; West China Hospital of Sichuan University

DOI：

10.7507/1672-2531.20140189

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To retrospectively investigate the drug use of over-60-year inpatients with lung cancer in the West China Hospital of Sichuan University in 2011, and to compare with outpatients with lung cancer concurrently, so as to evaluate the rationality of drug use among over-60-year inpatients with lung cancer in the West China Hospital. Methods The information of over-60-year inpatients with lung cancer as initial diagnosis in the West China Hospital in 2011 was collected from the hospital information system (HIS), including patient information, drug use information, cost information, etc. Data rearrangement and analysis by classes and costs were carried out using Microsoft Excel 2010 software. Results a) There was 2 215 person-times of over-60-year inpatients with lung cancer in the West China Hospital of Sichuan University in 2011. A total of 5 classes, 63 kinds of anti-tumor and adjuvant therapy drugs were involved. The total drug use frequency was 12 398 person-times. The average medicine cost was 774.93 yuan. b) The ratio of patients using 1 to 4 kinds of drugs was 34.31%, 5 to 10 kinds was 41.9%, and 11 to 15 kinds was 12.63%. c) For etiological treatment, the ratio of chemotherapy drugs was 99.45%, and the most used was cisplatin. d) For symptomatic treatment, the ratio of analgesics was 66.69%; the ratio of antitussive drugs was 21.33%; and the ratio of skeletal related events prevention drugs was 11.98%. e) For anti-ADR treatment, the ratio of antiemetic drugs was 55.07%; the ratio of stomach protection drugs was 32.63%; and the ratio of hepatic protection drugs was 12.30%. f) For other treatment, the ratio of immunopotentiating drugs was 59.46%; and the ratio of hematopoietic growth factor was 25.42%. g) For Chinese patent medicine, drugs used over 400 person-times were Diyushengbai tablet, Javanica oil emulsion injection, Aidi injection, and Huisheng oral liquid. h) For single/combined treatment, the ratio of two-drug combined chemotherapy was 78.38%, one analgesics drug treatment was 66.21%, one hepatic protection drug treatment was 83.41%, two-drug combined antanacathartic treatment was 45.88%, one stomach protection drug treatment was 90.53%, one immunopotentiating drug treatment was 90.53%, one hematopoietic growth factor treatment was 82.31%, and one Chinese patent medicine treatment was 37.39%, respectively; and antitussive and skeletal related events prevention drugs were used alone. i) The use frequency of the top 10 drugs were: pantoprazole, tropisetron, ondansetron, diphenhydramine, thymopentin, cisplatin, Diyushengbai tablet, tramadol, Javanica oil emulsion injection, and Aidi injection. j) Compared with outpatients, inpatients drug use frequency was higher in chemotherapy, analgesics, antiemetic, stomach protection, hepatic protection drugs, and Chinese patent medicine; but lower in skeletal related events prevention drug; and similar to the drug use situation of outpatients in immunopotentiating drugs and hematopoietic growth factor drugs. Conclusion The antitumor therapies were mainly the combination of two chemotherapy drugs or single drug regimen for over-60-year inpatients with lung cancer in the West China hospital of Sichuan University in 2011. The most frequently used adjuvant therapies are antalgic, antiemetic and stomach protection drugs. Chinese patent medicine and immunopotentiating drugs are in common use as well.

Citation： LUJing, XUTing, LIYou-ping, WUBin, YINXi, ZHANMei, XIAOGui-rong, ZHANGYing. Drug Use Analysis on Over-60-year Inpatients with Lung Cancer in the West China Hospital of Sichuan University in 2011. Chinese Journal of Evidence-Based Medicine, 2014, 14(10): 1171-1178. doi: 10.7507/1672-2531.20140189 Copy

1.	馬玉琴, 董剛, 熊林平, 等.我國老年醫療衛生服務保障研究:基于醫療衛生服務需求.中國衛生經濟, 2012, 31(7):20-22.
2.	徐珽, 盧靜, 李幼平, 等. 2011年四川大學華西醫院老年患者門診疾病構成調查.中國循證醫學雜志, 2013, 13(5):536-542.
3.	徐珽, 吳斌, 李幼平, 等. 2011年四川大學華西醫院老年患者住院疾病構成調查.中國循證醫學雜志, 2013, 13(6):680-686.
4.	International Statistical Classification of Diseases and Related Health Problems 10th Revision. Available at:http://apps.who.int/classifications/icd10/browse/2010/en.
5.	National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Non-small cell lung cancer, Version 2. 2012. Available at:http://www.nccn.com.
6.	de Castria TB, da Silva EM, Gois AF, et al. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev, 2013, 8:CD009256.
7.	Atmaca A, Al-Batran SE, Werner D, et al. A randomised multicentre phase Ⅱ study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer. Br J Cancer, 2013, 108(2):265-270.
8.	Li Z, Hou M, Wang H, et al. A randomized study of gemcitabine plus oxaliplatin versus gemcitabine plus cisplatin as the 1st line chemotherapy for advanced non-small cell lung cancer in elderly patients. Zhongguo Fei Ai Za Zhi, 2011, 14(7):588-592.
9.	蒲丹, 侯梅, 李之曦, 等.奧沙利鉑或順鉑聯合足葉乙甙治療老年廣泛期小細胞肺癌的隨機對照臨床研究.中國肺癌雜志, 2013, 16(1):20-24.
10.	曾曉梅, 李之曦, 侯梅.紫杉醇脂質體單藥與紫杉醇脂質體聯合奧沙利鉑一線治療老年晚期非小細胞肺癌的隨機對照研究.中國肺癌雜志, 2012, 15(2):84-89.
11.	儲天晴, 林皓, 沈潔, 等.單藥紫杉醇與紫杉醇聯合奧沙利鉑二線治療晚期非小細胞肺癌臨床療效比較.中國肺癌雜志, 2009, 12(11):1178-1183.
12.	National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Adult Cancer Pain, Version 2. 2013. Available at:http://www.nccn.com.
13.	郭靜波, 魏麗萍, 王玉梅.芬太尼透皮貼劑與口服嗎啡控釋片治療國人中重度癌痛臨床效果的Meta分析.中國衛生統計, 2010, 27(4):385-387.
14.	繆曉輝.保肝治療:共識與爭議.肝臟, 2010, 15(3):202-203.
15.	李磊.鹽酸托烷司瓊預防肺癌患者化療所致惡心嘔吐的臨床研究.中國當代醫藥, 2011, 18(17):71-72.
16.	陳冠容, 劉立. 2005~2007年長江流域6城市胸腺肽類藥使用分析及安全性評估.藥物流行病學雜志, 2009, 18(1):43-45.
17.	韓慧杰, 朱霞.重組人粒細胞集落刺激因子治療化療后白細胞減少療效觀察.醫藥論壇雜志, 2011, 32(22):132-133.
18.	王鴻蘊, 王煊, 朱文濤.中成藥說明書與美國藥品說明書對比研究.中國藥物評價, 2013, 30(2):73-76.
19.	董爽, 于世英.腫瘤化療所致惡心嘔吐現狀調查.中國循證醫學雜志, 2013, 13(6):687-691.
20.	楊曉軍, 李朝暉.采用DDD和DUI法分析我院門診抗感染藥物利用情況.現代應用藥學, 1997, 14(1):60-62.

1. 馬玉琴, 董剛, 熊林平, 等.我國老年醫療衛生服務保障研究:基于醫療衛生服務需求.中國衛生經濟, 2012, 31(7):20-22.
2. 徐珽, 盧靜, 李幼平, 等. 2011年四川大學華西醫院老年患者門診疾病構成調查.中國循證醫學雜志, 2013, 13(5):536-542.
3. 徐珽, 吳斌, 李幼平, 等. 2011年四川大學華西醫院老年患者住院疾病構成調查.中國循證醫學雜志, 2013, 13(6):680-686.
4. International Statistical Classification of Diseases and Related Health Problems 10th Revision. Available at:http://apps.who.int/classifications/icd10/browse/2010/en.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Non-small cell lung cancer, Version 2. 2012. Available at:http://www.nccn.com.
6. de Castria TB, da Silva EM, Gois AF, et al. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database Syst Rev, 2013, 8:CD009256.
7. Atmaca A, Al-Batran SE, Werner D, et al. A randomised multicentre phase Ⅱ study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer. Br J Cancer, 2013, 108(2):265-270.
8. Li Z, Hou M, Wang H, et al. A randomized study of gemcitabine plus oxaliplatin versus gemcitabine plus cisplatin as the 1st line chemotherapy for advanced non-small cell lung cancer in elderly patients. Zhongguo Fei Ai Za Zhi, 2011, 14(7):588-592.
9. 蒲丹, 侯梅, 李之曦, 等.奧沙利鉑或順鉑聯合足葉乙甙治療老年廣泛期小細胞肺癌的隨機對照臨床研究.中國肺癌雜志, 2013, 16(1):20-24.
10. 曾曉梅, 李之曦, 侯梅.紫杉醇脂質體單藥與紫杉醇脂質體聯合奧沙利鉑一線治療老年晚期非小細胞肺癌的隨機對照研究.中國肺癌雜志, 2012, 15(2):84-89.
11. 儲天晴, 林皓, 沈潔, 等.單藥紫杉醇與紫杉醇聯合奧沙利鉑二線治療晚期非小細胞肺癌臨床療效比較.中國肺癌雜志, 2009, 12(11):1178-1183.
12. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), Adult Cancer Pain, Version 2. 2013. Available at:http://www.nccn.com.
13. 郭靜波, 魏麗萍, 王玉梅.芬太尼透皮貼劑與口服嗎啡控釋片治療國人中重度癌痛臨床效果的Meta分析.中國衛生統計, 2010, 27(4):385-387.
14. 繆曉輝.保肝治療:共識與爭議.肝臟, 2010, 15(3):202-203.
15. 李磊.鹽酸托烷司瓊預防肺癌患者化療所致惡心嘔吐的臨床研究.中國當代醫藥, 2011, 18(17):71-72.
16. 陳冠容, 劉立. 2005~2007年長江流域6城市胸腺肽類藥使用分析及安全性評估.藥物流行病學雜志, 2009, 18(1):43-45.
17. 韓慧杰, 朱霞.重組人粒細胞集落刺激因子治療化療后白細胞減少療效觀察.醫藥論壇雜志, 2011, 32(22):132-133.
18. 王鴻蘊, 王煊, 朱文濤.中成藥說明書與美國藥品說明書對比研究.中國藥物評價, 2013, 30(2):73-76.
19. 董爽, 于世英.腫瘤化療所致惡心嘔吐現狀調查.中國循證醫學雜志, 2013, 13(6):687-691.
20. 楊曉軍, 李朝暉.采用DDD和DUI法分析我院門診抗感染藥物利用情況.現代應用藥學, 1997, 14(1):60-62.

Chinese Journal of Evidence-Based Medicine

Drug Use Analysis on Over-60-year Inpatients with Lung Cancer in the West China Hospital of Sichuan University in 2011

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content